Neurology | Preclinical Developments

Coda Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

CODA Biotherapeutics Announces Research Collaboration With The Facial Pain Research Foundation

Lead Product(s): Aav Vectors

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Gene therapy

Partner/Sponsor/Collaborator: Facial Pain Research Foundation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 20, 2020

Details:

Strategic partnership supports CODA's efforts to develop gene-therapy mediated treatments and cures for trigeminal neuralgia and related neuropathic pain.

QurAlis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

QurAlis Nabs $42M Funding Round for ALS, Frontotemporal Dementia

Lead Product(s): Stem cell therapy

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Polaris Partners

Deal Size: $42.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing May 13, 2020

Details:

QurAlis intends to use this funding to support the development of new therapies for ALS and genetically related frontotemporal dementia (FTD), neurodegenerative diseases for which there is currently no cure.

DTx Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS

Lead Product(s): siRNAs

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Gene therapy

Partner/Sponsor/Collaborator: Alzheimer's Association

Deal Size: $0.4 million Upfront Cash: Undisclosed

Deal Type: Funding May 13, 2020

Details:

The award, along with prior and pending grants, will enable DTx to expand the application of its lipid conjugate technology for the delivery of oligonucleotides as potential treatment for neurodegenerative diseases.

Alpha Cognition

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Alpha Cognition Inc. Announces Granted EU Patents and Orphan Drug Designation for Its Progranulin Platform

Lead Product(s): Progranulin

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2020

Details:

Alpha Cognition has been granted 2 EU patents relating to the use of progranulin to treat neurodegenerative diseases. Progranulin, alpha-602, is a protein, capable of protecting stressed neurons.

Seelos Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)

Lead Product(s): Trehalose API

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

The allowed claims cover the composition of matter and method of use for trehalose (SLS-005) for treating diseases or disorders which include Spinal and bulbar muscular atrophy (SBMA) and other.

VBL Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation

Lead Product(s): VB-601

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

VBL Therapeutics's anti-MOSPD2 antibodies that block monocyte migration without affecting T-cells, were able to recapitulate this effect and profoundly reduced inflammation and tissue damage.

Prevail Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Prevail Therapeutics to Highlight Multiple CNS-Focused Gene Therapy Programs at 2020 American Society of Gene & Cell Therapy Annual Meeting

Lead Product(s): PR001

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 29, 2020

Details:

Preclinical data demonstrate potential of Prevail’s AAV gene therapy approach to slow or halt progression in multiple neurodegenerative diseases.

Flexion Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301 for Post-Operative Pain

Lead Product(s): Funapide

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo.

NeuroBo Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders

Lead Product(s): NB-02

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 21, 2020

Details:

The patent covers the extract of a mixture containing mulberry and Poria cocos peel, active ingredients contained in the composition, for treating a degenerative neurological disease.

Stealth Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Stealth Biotherapeutics Announces $20 Million Financing to Advance Development of Elamipretide and Pipeline

Lead Product(s): SBT-272

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Morningside Venture

Deal Size: $20.0 million Upfront Cash: Undisclosed

Deal Type: Financing April 13, 2020

Details:

The Company expects to use proceeds from this capital raise to advance the Company's ongoing development of its lead candidate, elamipretide, its next-generation clinical stage compound, SBT-272.

Find

Find Novel Neurology Drugs in Preclinical Development

Preclinical

A collaboration with SCORR Marketing

Product Type

Companies

Coda Biotherapeutics

CODA Biotherapeutics Announces Research Collaboration With The Facial Pain Research Foundation

QurAlis

QurAlis Nabs $42M Funding Round for ALS, Frontotemporal Dementia

DTx Pharma

DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS

Alpha Cognition

Alpha Cognition Inc. Announces Granted EU Patents and Orphan Drug Designation for Its Progranulin Platform

Seelos Therapeutics

Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)

VBL Therapeutics

VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation

Prevail Therapeutics

Prevail Therapeutics to Highlight Multiple CNS-Focused Gene Therapy Programs at 2020 American Society of Gene & Cell Therapy Annual Meeting

Flexion Therapeutics

Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301 for Post-Operative Pain

NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders

Stealth Biotherapeutics

Stealth Biotherapeutics Announces $20 Million Financing to Advance Development of Elamipretide and Pipeline